Dialogues on AI Digital Pathology – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Dialogues on AI Digital Pathology

HistoIndex

News

Frequency: 1 episode/20d. Total Eps: 16

Dialogues on AI Digital Pathology is a podcast/webinar series where medical and industry experts will be sharing their views on the evolving trends of AI digital pathology and its role in finding effective treatments for Nonalcoholic Steatohepatitis (NASH). Featured Music by Kevin MacLeod Cover Art Image by Matt Botsford on Unsplash

Read moreCollapse

Site

RSS

Apple

Data updated on 04/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.histoindex.com/news-room/dialogues-ai-digital-pathology/special-episode-part-4-conversation-with-kol-hepatologists-and-pharma-thought-leaders-in-nash/
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 58%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Special Episode (PART 4) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASH

Season 2 · Episode 4

Monday, June 7, 2021 • Duration 49:38

We’re very happy to bring you Part 4 that will wrap up the Special Episode podcast of Dialogues on AI Digital Pathology!

In this Part 4 podcast, our guests – KOL Hepatologists and Pharma Thought Leaders in NASH – continue their discussions in response to questions by Pharma companies and clinical investigators. Find out their views on how AI Digital Pathology (AI-DP) can effectively impact NASH drug development, preclinical studies and clinical practice with granular histopathological data.

Please click here to view the Key Takeaways for Part 4 or go to https://tinyurl.com/b4ttvb4s.

Our thanks and appreciation to our guest KOL hepatologists, thought leaders in NASH pharma and moderator!

Guests

Prof. Stephen Harrison (Pinnacle Clinical Research)

Prof. Vlad Ratziu (Sorbonne University Pitié-Salpêtrière Hospital)

Dr. Judith Ertle (Boehringer Ingelheim)

Dr. Karin Conde-Knape (Novo Nordisk)

Absent with Apologies - Ms. Kitty Yale (Akero Therapeutics)

Moderator

Dr. Nikolai Naoumov (Novartis)

Read moreCollapse

[Official Trailer] Special Episode (PART 4) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASH

Season 2 · Episode 4

Thursday, June 3, 2021 • Duration 03:44

Dialogues on AI Digital Pathology is releasing Part 4 of its Special Episode real soon!

Listen to this trailer for a snippet of Part 4 with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they continue their discussions on AI Digital Pathology (AI-DP), and the application and future of AI-DP in clinical practice, liver research, and drug development.

Guests

Prof. Stephen Harrison, Medical Director, Pinnacle Clinical Research

Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne University and Pitié-Salpêtrière Hospital

Dr. Judith Ertle, Senior Clinical Program Lead NASH, Boehringer Ingelheim

Dr. Karin Conde-Knape, ‎Senior Vice President Global Drug Discovery, Novo Nordisk

Absent with Apologies

Ms. Kitty Yale, EVP and Chief Development Officer, Akero Therapeutics

Moderator

Dr. Nikolai Naoumov, Senior Adviser, Clinical Research and Drug Development in Liver Diseases, Novartis

Do remember to Subscribe to our Podcast to receive updates on new episodes!

Read moreCollapse

Special Episode (PART 3) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASH

Season 2 · Episode 3

Monday, May 17, 2021 • Duration 57:54

Guests

Prof. Stephen Harrison (Pinnacle Clinical Research)

Prof. Vlad Ratziu (Sorbonne University Pitié-Salpêtrière Hospital)

Dr. Judith Ertle (Boehringer Ingelheim)

Dr. Karin Conde-Knape (Novo Nordisk)

Ms. Kitty Yale (Akero Therapeutics)

Moderator

Dr. Nikolai Naoumov (Novartis)

Key Takeaways

1) The innovation and qualities that AI Digital Pathology (AI-DP) brings to drug development can be described as a disruptive technology as it expands the knowledge of NASH pathobiology, introduces standardization and reproducibility on a fully quantitative scale, allows to better define a dose-response to compounds with different Mechanism of Action (MoA) and regression or progression of NASH disease. In addition, AI-DP has the potential to stabilize placebo response rates and provide a better understanding of how the drugs are working in dose-dependent responses.

2) AI digital pathology brings two key novelties: firstly, it provides better understanding of liver injury, both for the clinical practice and for clinical trials with a robust and reproducible reading of NASH features and avoids the intra- and inter-observer variabilities; secondly, at a discovery level, AI-DP uncovers new parameters and greater details that cannot be detected by the human eye.

3) The use of AI-DP is not intended to replace routine pathology review of liver biopsies. It augments the information from conventional pathology by providing a standardised reading, helps reducing the rate of screen-failures as well as ensuring a more precise, granular quantitation of treatment response. AI-DP will be particularly valuable in clinical trials involving patients with cirrhotic NASH (as they have a wide range of collagen deposition) by providing quantitative understanding of collagen dynamics within F4 stage and accurate assessment of treatment efficacy.

[Official Trailer] Special Episode (PART 3) - Conversation with KOL Hepatologists and Pharma Thought Leaders in NASH

Season 2 · Episode 3

Friday, May 14, 2021 • Duration 03:44

Our Special Episode conversation on AI Digital Pathology in NASH Drug Development continues (in Parts 3 and 4) with our guests, KOL hepatologists and Pharma Thought Leaders in NASH, as they respond to questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can augment clinical trial data and work alongside pathologists to detect granular information that could be pivotal for determining patient recruitment, staging and treatment responses. The full Part 3 podcast will be launched early next week, so click here to listen to the Trailer of Part 3!

A huge Thank You to our Guests and Moderator for their kind participation and professional views spoken in this entire Special Episode!

Guests

Prof. Stephen Harrison, Medical Director, Pinnacle Clinical Research

Prof. Vlad Ratziu, Professor of Hepatology, Sorbonne University and Pitié-Salpêtrière Hospital

Dr. Judith Ertle, Senior Clinical Program Lead NASH, Boehringer Ingelheim

Dr. Karin Conde-Knape, ‎Senior Vice President Global Drug Discovery, Novo Nordisk

Ms. Kitty Yale, EVP and Chief Development Officer, Akero Therapeutics

Moderator

Dr. Nikolai Naoumov, Senior Adviser, Clinical Research and Drug Development in Liver Diseases, Novartis

Do remember to Subscribe to our Podcast to receive updates on new episodes!

Read moreCollapse

Special Episode (PART 2) - Conversation with KOL Liver Pathologists

Season 2 · Episode 2

Wednesday, March 17, 2021 • Duration 40:55

Our guest KOL liver pathologists continue their conversation from Part 1 following the FDA Webcast, by responding to more questions by Pharma companies and clinical investigators on how AI Digital Pathology (AI-DP) can aid pathologists with precise assessment to better interpret the disease biology of NASH.

We’d like to thank our Guests and Moderator for their kind participation and professional views!

Prof. Pierre Bedossa

Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France

Prof. Zachary Goodman

Director of Hepatic Pathology Consultation and Research, Inova Fairfax Hospital, Falls Church, Virginia, USA

Prof. David Kleiner

Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, Center for Cancer Research,

National Cancer Institute, Bethesda, Maryland, USA

Moderator

Dr. Nikolai Naoumov

Adviser for Clinical Research and Drug Development in Liver Diseases, Novartis Pharma AG

Key Takeaways from the KOLs in this Special Episode (Part 2)

- According to the KOLs, regression of disease is not well delineated or understood. AI-DP offers new insights into the biology of NASH and additional information especially in the identification of ballooned hepatocytes, quantification of peri-sinusoidal fibrosis, septa quantification and others.

[Official Trailer] Special Episode (PART 2) - Conversation with KOL Liver Pathologists

Season 2 · Episode 2

Friday, March 12, 2021 • Duration 03:48

Here's the Official Trailer for Part 2 of our Special Episode of Dialogues on AI Digital Pathology, which is coming up in a week! Listen to these sound bites from our guest KOL liver pathologists, Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov about AI digital pathology as a complementary tool for pathologists in interpreting the disease biology of NASH. This is a continuation from Part 1, where the KOLs commented on the key takeaways from the recent FDA webcast on NASH Drug Development, and questions from the industry on designing clinical trial strategies with AI digital pathology. Do listen to their conversation in Part 1 if you haven't!

Guests

Prof. Pierre Bedossa

Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France.

Prof. Zachary Goodman

Director of Hepatic Pathology Consultation and Research, Inova Fairfax Hospital, Falls Church, Virginia, USA.

Prof. David Kleiner

Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, Center for Cancer Research,

National Cancer Institute, Bethesda, Maryland, USA.

Moderator

Dr. Nikolai Naoumov

Adviser for Clinical Research and Drug Development in Liver Diseases, Novartis Pharma AG

Read moreCollapse

Special Episode (PART 1) - Conversation with KOL Liver Pathologists

Season 2 · Episode 1

Tuesday, March 9, 2021 • Duration 57:05

We’re very excited to bring you a Two-Part Special Episode of Dialogues on AI Digital Pathology!

Listen to our guests, KOL liver pathologists as they discuss the recent FDA Webcast on NASH drug development and utilization of AI digital pathology as potential clinical trial endpoints.

Here’s Part 1, where the KOL liver pathologists will discuss key takeaways from the recent FDA Webcast on NASH Drug Development, and respond to questions sent in by Pharma companies and clinical investigators on potential clinical trial strategies using AI digital pathology following the Webcast.

Guests

Prof. Pierre Bedossa

Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France.

Prof. Zachary Goodman

Director of Hepatic Pathology Consultation and Research, Inova Fairfax Hospital, Falls Church, Virginia, USA.

Prof. David Kleiner

Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, Center for Cancer Research,

National Cancer Institute, Bethesda, Maryland, USA.

Moderator

Dr. Nikolai Naoumov

Adviser for Clinical Research and Drug Development in Liver Diseases, Novartis Pharma AG

[Official Trailer] Special Episode (PART 1) - Conversation with KOL Liver Pathologists

Season 2 · Episode 1

Friday, March 5, 2021 • Duration 03:50

We're commencing a two-part Special Episode of Dialogues on AI Digital Pathology!

This episode brings together our guests, Key Opinion Leaders in liver pathology, who will be speaking about the key takeaways from the recent FDA webcast on NASH Drug Development, and responding to questions from the industry on designing clinical trial strategies with AI digital pathology. Here's a Trailer of Part 1 with snippets from Professor Pierre Bedossa, Professor Zachary Goodman, and Professor David Kleiner as they speak to our Moderator, Dr Nikolai Naoumov.

Guests

Prof. Pierre Bedossa

Professor of Pathology at the University of Paris; Consultant in Liver Pathology at LIVERPAT, Paris, France.

Prof. Zachary Goodman

Director of Hepatic Pathology Consultation and Research, Inova Fairfax Hospital, Falls Church, Virginia, USA.

Prof. David Kleiner

Senior Research Physician and Chief of Post-mortem Section, Laboratory of Pathology, Center for Cancer Research,

National Cancer Institute, Bethesda, Maryland, USA.

Moderator

Dr. Nikolai Naoumov

Adviser for Clinical Research and Drug Development in Liver Diseases, Novartis Pharma AG

Read moreCollapse

Episode 4 with Dr. Nikolai Naoumov [Full Podcast]

Season 1 · Episode 4

Tuesday, December 8, 2020 • Duration 39:24

In this episode*, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis, and physician-scientist and specialist in liver diseases). With his current focus on AI digital pathology in assessing liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai speaks to us on the changing landscape of drug development for NASH fuelled by advances in AI digital pathology.

*This episode concludes Season 1 of Dialogues on AI Digital Pathology, and we will be commencing our second podcast season in mid-2021. Meanwhile, the webinars series on AI Digital Pathology in both NASH preclinical studies and clinical trials will commence in the first half of 2021. We’ll keep you posted on our webinars.

Do remember to hit the Subscribe or Follow buttons at the following platforms to be updated when the Podcast’s Season 2 begins!

Read moreCollapse

[Official Trailer] Episode 4 with Dr. Nikolai Naoumov

Season 1 · Episode 4

Wednesday, December 2, 2020 • Duration 02:11

In the upcoming episode 4 of Dialogues on AI Digital Pathology, we speak to Dr. Nikolai Naoumov, MD, PhD, FRCP, FRCPAth, FAASLD (Adviser for Clinical Research and Drug Development in Liver Diseases at Novartis). Nikolai is a physician-scientist with a professional career combining academic research, clinical care and drug development – all focused on liver diseases. With his current work focusing on digital pathology with AI assessment of liver biopsies, NASH combination therapies, HBV cure and liver fibrosis, Nikolai shares his views about the advantages and impact of AI digital pathology in drug development efforts for NASH.

Read moreCollapse

Dialogues on AI Digital Pathology – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Dialogues on AI Digital Pathology – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

X1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

X1

Apple Podcasts

Spotify